TITLE

Roche In-Licenses Galaxy Biotech's Preclinical FGF2 Antibody Programme

AUTHOR(S)
Cartwright, Heather
PUB. DATE
October 2012
SOURCE
PharmaDeals Review;2012, Vol. 2012 Issue 10, p130
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that Roche has licensed international rights to the preclinical-stage antibodies of Galaxy Biotech targeting fibroblast growth factor 2 (FGF2) in cancer metastasis. It states that Roche will be responsible for the development and commercialisation of the project and will pay Galaxy with U.S.$8 million upfront, with additional potential milestone payments and royalties. It adds that the deal followed the termination of Takeda Pharmaceutical's license agreement with Galaxy.
ACCESSION #
87717880

 

Related Articles

  • ROCHE/GLYCART TO DISCOVER NEW THERAPEUTIC ANTIBODIES.  // Worldwide Biotech;Nov2004, Vol. 16 Issue 11, p5 

    Reports on the agreement between Roche and GLYCART to discover next-generation therapeutic antibodies using GlycoMabTM technology. Terms of the agreement; Factors that influenced Roche to license GlycoMabTM; Profile of GLYCART and Roche; Information on GlycoMab.

  • Cancer News Round-Up.  // PharmaWatch: Monthly Review;Mar2010, Vol. 9 Issue 3, p4 

    The article offers updates on drug development for cancer. Pfizer Inc. has released results of the Phase III trial for its Sutent drug for treatment of advanced pancreatic neuroendocrine tumors. Takeda Pharmaceutical Co. Ltd.'s Mepact, a new treatment for osteosarcoma, is already available in...

  • Roche chooses to develop Genmab antibodies.  // PharmaWatch: Biotechnology;May 2004, Vol. 3 Issue 5, p8 

    Focuses on the selection of two Genmab AS antibodies by Roche as candidates for clinical development. Terms of the agreement; Production of antibody product candidates; Effectivity of the development of antibodies.

  • Dalcetrapib.  // Drugs in R&D;2010, Vol. 10 Issue 1, p33 

    Roche and Japan Tobacco are in a licensing agreement to develop and commercialize dalcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor to slow or prevent atherosclerosis. This drug is currently in phase III development. This review discusses the development history and scientific...

  • Roche and Japan Tobacco collaborate over dyslipidemia therapy.  // PharmaWatch: Biotechnology;December2004, Vol. 3 Issue 12, p19 

    Reports the licensing agreement between Roche Pharmaceuticals and Japan Tobacco Inc. for the late-stage development and commercialization of an innovative cholesterol modifying agent, a potential therapy for treatment of dyslipidemia. Terms of the agreement; Benefits for both parties; Prevalence...

  • MDRNA signs licensing agreement with Roche.  // PharmaWatch: Biotechnology;Apr2009, Vol. 8 Issue 4, p18 

    The article reports on the signing of a licensing agreement by MDRNA Inc. and Roche Pharmaceuticals. The licensing agreement is consistent to which Roche will get a non-exclusive license to a portion of MDRNA's technology platform for the development of ribonucleic acid interference-based...

  • Roche pulls out of alliance with Basilea for new antibiotic.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p17 

    Reports on the strategic alliance of Roche Pharmaceutical Co. with Basilea Pharmaceutica Ltd. for the development of new antibiotic drug. Terms under the deal; Benefits of the agreement for both companies; Significance of the deal for pharmaceutical biotechnology industry.

  • Adimab Yeast-Based Platform Draws Big Pharma's Attention. Hollingsworth, Catherine // BioWorld Today;6/22/2009, Vol. 20 Issue 118, p1 

    This article reveals that Adimab Inc. has successfully secured two major drug discovery deals in June 2009. In addition, the company is involved in negotiations with several major drugmakers for possible collaborations in the future. Particular focus is gievn to the company's business model....

  • Other News To Note.  // BioWorld Today;12/13/2010, Vol. 21 Issue 239, p4 

    This section offers news briefs on the biotechnology industry including the license agreement signed between Serodus A/S and Roche AG and the finalization of a buyout offer by Spencer Pharmaceuticals Inc. of Al-Dorra Group.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics